Publicaciones en colaboración con investigadores/as de Yale School of Medicine (20)

2024

  1. Comparing Survival of Perihilar Cholangiocarcinoma After R1 Resection Versus Palliative Chemotherapy for Unresected Localized Disease

    Annals of Surgical Oncology

  2. Event-free survival of maralixibat-treated patients with Alagille syndrome compared to a real-world cohort from GALA

    Hepatology (Baltimore, Md.), Vol. 79, Núm. 6, pp. 1279-1292

2023

  1. A TGFβ-ECM-integrin signaling axis drives structural reconfiguration of the bile duct to promote polycystic liver disease

    Science translational medicine, Vol. 15, Núm. 713, pp. eabq5930

  2. A second update on mapping the human genetic architecture of COVID-19

    Nature

  3. Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance

    Nature Reviews Gastroenterology and Hepatology, Vol. 20, Núm. 7, pp. 462-480

  4. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

    Nature Medicine, Vol. 29, Núm. 3, pp. 632-645

2022

  1. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry

    Journal of Hepatology, Vol. 76, Núm. 5, pp. 1109-1121

  2. Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models

    Journal of Hepatology, Vol. 77, Núm. 1, pp. 177-190

2021

  1. Neutrophils interact with cholangiocytes to cause cholestatic changes in alcoholic hepatitis

    Gut, Vol. 70, Núm. 2, pp. 342-356

  2. rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis

    Journal of Hepatology, Vol. 74, Núm. 1, pp. 20-30

2020

  1. CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity

    Immunity, Vol. 52, Núm. 5, pp. 856-871.e8

  2. Cholangiocarcinoma 2020: the next horizon in mechanisms and management

    Nature Reviews Gastroenterology and Hepatology, Vol. 17, Núm. 9, pp. 557-588

  3. Type 3 Inositol 1,4,5-Trisphosphate Receptor Is Increased and Enhances Malignant Properties in Cholangiocarcinoma

    Hepatology, Vol. 71, Núm. 2, pp. 583-599

2019

  1. Cholangiocyte pathobiology

    Nature Reviews Gastroenterology and Hepatology, Vol. 16, Núm. 5, pp. 269-281

  2. Effects of Endotoxin on Type 3 Inositol 1,4,5-Trisphosphate Receptor in Human Cholangiocytes

    Hepatology, Vol. 69, Núm. 2, pp. 817-830

2018

  1. Liquid Biopsy: From Basic Research to Clinical Practice

    Advances in Clinical Chemistry (Academic Press Inc.), pp. 73-119

  2. MicroRNA-506 promotes primary biliary cholangitis–like features in cholangiocytes and immune activation

    Hepatology, Vol. 67, Núm. 4, pp. 1420-1440

2017

  1. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97

2016

  1. Abscopal effects of radiotherapy are enhanced by combined immunostimulatory mAbs and are dependent on CD8 T cells and crosspriming

    Cancer Research, Vol. 76, Núm. 20, pp. 5994-6005

2015

  1. Post-translational regulation of the type III inositol 1,4,5-trisphosphate receptor by miRNA-506

    Journal of Biological Chemistry, Vol. 290, Núm. 1, pp. 184-196